Atopic dermatitis (AD) is a chronic inflammatory skin condition that involves a significant breakdown of the epidermal barrier. Recently, researchers have identified that the skin microbiota in AD plays a critical role in disease progression. While healthy skin hosts a diverse community of microbes like Cutibacterium acnes, AD skin often lacks this vital variety. Instead, a single pathogen typically dominates the landscape, leading to persistent inflammation and patient discomfort.

The Impact of Skin Microbiota in AD Pathogenesis

The dominance of Staphylococcus aureus remains a central feature of the disease. This bacterium utilizes the accessory gene regulator (Agr) system to communicate and coordinate its virulence. Specifically, this quorum-sensing system triggers the production of δ-toxin, which directly damages keratinocytes. Consequently, this process worsens type 2 inflammation and further weakens the skin barrier. Notably, early life colonization with these virulent strains significantly increases the risk of developing chronic AD later in childhood.

Restoring Balance Through Targeted Therapies

Traditional treatments often rely on broad-spectrum antibiotics, but these can unintentionally kill beneficial bacteria. Because of this, medical experts are now exploring microbiome-targeted interventions. For example, bacteriotherapy uses healthy commensal strains to inhibit the growth of S. aureus naturally. Additionally, researchers are developing quorum-quenching agents to disable bacterial virulence without inducing resistance. Finally, clinicians are investigating preventive skincare in infancy to foster a robust microbiome from the start.

Frequently Asked Questions

What is the role of the Agr system in AD?

The Agr system is a quorum-sensing mechanism that regulates the production of toxins in S. aureus, which worsens skin inflammation and barrier defects.

How does bacteriotherapy help in Atopic Dermatitis?

Bacteriotherapy involves applying beneficial bacteria to the skin to restore diversity and naturally suppress harmful pathogens like S. aureus without the side effects of antibiotics.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Okamoto H et al. Dysbiosis in the Pathogenesis of Atopic Dermatitis. J Dermatol. 2026 Feb 20. doi: 10.1111/1346-8138.70191. PMID: 41721459.

2. Nakatsuji T et al. Microbiome dysbiosis and therapeutic restoration in atopic dermatitis. Frontiers in Medicine. 2025;12:154321.

3. Nakatsuji T et al. Use of autologous bacteriotherapy to treat Staphylococcus aureus in patients with atopic dermatitis: a randomized double-blind clinical trial. JAMA Dermatol. 2021;157(8):978-982.